DPP-IV inhibitors derived from plants may be developed as dietary supplements to minimize the risk of developing hyperglycemia or they may be used with anti-diabetic medications currently approved for glycemic management in T2DM; however, additional research is required to determine the strategies that will result in economically producible levels of these inhibitors. This evidence concerns the gene ST6GALNAC4 and Hyperglycemia.